Klehmet, Juliane
Tackenberg, Björn
Haas, Judith
Kieseier, Bernd C.
Funding for this research was provided by:
Grifols
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 20 September 2022
Accepted: 22 April 2023
First Online: 26 May 2023
Declarations
:
: The study protocol was approved by the ethics committee of the Charité University Hospital (Berlin, Germany). This study was carried out in compliance with an observational plan, regulatory requirements, and the ethical principles of the latest revision of the Declaration of Helsinki as adopted by the World Medical Association. The study was conducted in accordance with the German Medicinal Products Act and followed the recommendations of the Paul-Ehrlich-Institute and the German Federal Institute for Drugs and Medical Devices. Prior to study enrolment, written informed consent was obtained from each patient.
: Not applicable.
: JK has received personal compensation for activities associated with Grifols, CSL Behring and Octapharma, and has received research support from Grifols and Octapharma. BT has received personal compensation for lecturing, consulting services and travel expenses from Bayer Healthcare, Biogen-idec, CSL Behring, Grifols, Merck Serono, Novartis, Octapharma, Roche, Sanofi Genzyme, TEVA and UCB Pharma. There have been different research cooperation’s with Biogen-idec, Novartis, TEVA, Bayer Healthcare, CSL-Behring, Grifols, Octapharma, Sanofi Genzyme and UCB Pharma. JH declares no conflict of interest. BCK has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen, Genzyme/Sanofi Aventis, Grifols, Merck Serono, Mitsubishi Europe, Novartis, Roche, Talecris, and TEVA. He is currently also employee of Biogen.